JP2007509941A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007509941A5 JP2007509941A5 JP2006538128A JP2006538128A JP2007509941A5 JP 2007509941 A5 JP2007509941 A5 JP 2007509941A5 JP 2006538128 A JP2006538128 A JP 2006538128A JP 2006538128 A JP2006538128 A JP 2006538128A JP 2007509941 A5 JP2007509941 A5 JP 2007509941A5
- Authority
- JP
- Japan
- Prior art keywords
- inhaler
- medicament
- pharmaceutical formulation
- combinations
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 claims 23
- 239000008194 pharmaceutical composition Substances 0.000 claims 21
- 229940125388 beta agonist Drugs 0.000 claims 18
- -1 anti-inflammatory Chemical compound 0.000 claims 17
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 claims 15
- 239000002260 anti-inflammatory agent Substances 0.000 claims 15
- 150000002148 esters Chemical class 0.000 claims 12
- 150000003839 salts Chemical class 0.000 claims 12
- 239000012453 solvate Substances 0.000 claims 12
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 10
- 229960000289 fluticasone propionate Drugs 0.000 claims 9
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 claims 9
- 229960005018 salmeterol xinafoate Drugs 0.000 claims 9
- 238000009472 formulation Methods 0.000 claims 8
- 239000000203 mixture Substances 0.000 claims 8
- XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 claims 6
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 claims 6
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 claims 6
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims 6
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 claims 6
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 claims 6
- BNPSSFBOAGDEEL-UHFFFAOYSA-N albuterol sulfate Chemical compound OS(O)(=O)=O.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 BNPSSFBOAGDEEL-UHFFFAOYSA-N 0.000 claims 6
- 229940092705 beclomethasone Drugs 0.000 claims 6
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 claims 6
- 229960004436 budesonide Drugs 0.000 claims 6
- 229960000676 flunisolide Drugs 0.000 claims 6
- 229960002714 fluticasone Drugs 0.000 claims 6
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 claims 6
- 229960002848 formoterol Drugs 0.000 claims 6
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 claims 6
- 229960001664 mometasone Drugs 0.000 claims 6
- QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 claims 6
- MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 claims 6
- 229960002052 salbutamol Drugs 0.000 claims 6
- 229960004017 salmeterol Drugs 0.000 claims 6
- 229960000195 terbutaline Drugs 0.000 claims 6
- 229960005294 triamcinolone Drugs 0.000 claims 6
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 claims 6
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 claims 3
- AKNNEGZIBPJZJG-MSOLQXFVSA-N (-)-noscapine Chemical compound CN1CCC2=CC=3OCOC=3C(OC)=C2[C@@H]1[C@@H]1C2=CC=C(OC)C(OC)=C2C(=O)O1 AKNNEGZIBPJZJG-MSOLQXFVSA-N 0.000 claims 3
- YREYLAVBNPACJM-UHFFFAOYSA-N 2-(tert-butylamino)-1-(2-chlorophenyl)ethanol Chemical compound CC(C)(C)NCC(O)C1=CC=CC=C1Cl YREYLAVBNPACJM-UHFFFAOYSA-N 0.000 claims 3
- LSLYOANBFKQKPT-DIFFPNOSSA-N 5-[(1r)-1-hydroxy-2-[[(2r)-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]benzene-1,3-diol Chemical compound C([C@@H](C)NC[C@H](O)C=1C=C(O)C=C(O)C=1)C1=CC=C(O)C=C1 LSLYOANBFKQKPT-DIFFPNOSSA-N 0.000 claims 3
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 claims 3
- 229940097420 Diuretic Drugs 0.000 claims 3
- HUYWAWARQUIQLE-UHFFFAOYSA-N Isoetharine Chemical compound CC(C)NC(CC)C(O)C1=CC=C(O)C(O)=C1 HUYWAWARQUIQLE-UHFFFAOYSA-N 0.000 claims 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 3
- WUGQZFFCHPXWKQ-UHFFFAOYSA-N Propanolamine Chemical compound NCCCO WUGQZFFCHPXWKQ-UHFFFAOYSA-N 0.000 claims 3
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims 3
- 229940057282 albuterol sulfate Drugs 0.000 claims 3
- AKNNEGZIBPJZJG-UHFFFAOYSA-N alpha-noscapine Natural products CN1CCC2=CC=3OCOC=3C(OC)=C2C1C1C2=CC=C(OC)C(OC)=C2C(=O)O1 AKNNEGZIBPJZJG-UHFFFAOYSA-N 0.000 claims 3
- 230000000202 analgesic effect Effects 0.000 claims 3
- 230000000954 anitussive effect Effects 0.000 claims 3
- 230000003257 anti-anginal effect Effects 0.000 claims 3
- 230000001078 anti-cholinergic effect Effects 0.000 claims 3
- 230000001387 anti-histamine Effects 0.000 claims 3
- 230000002924 anti-infective effect Effects 0.000 claims 3
- 230000003110 anti-inflammatory effect Effects 0.000 claims 3
- 239000000739 antihistaminic agent Substances 0.000 claims 3
- 229940124584 antitussives Drugs 0.000 claims 3
- 229950000210 beclometasone dipropionate Drugs 0.000 claims 3
- 229940124630 bronchodilator Drugs 0.000 claims 3
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 claims 3
- 229960003957 dexamethasone Drugs 0.000 claims 3
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 3
- PCHPORCSPXIHLZ-UHFFFAOYSA-N diphenhydramine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(OCC[NH+](C)C)C1=CC=CC=C1 PCHPORCSPXIHLZ-UHFFFAOYSA-N 0.000 claims 3
- 239000002934 diuretic Substances 0.000 claims 3
- 230000001882 diuretic effect Effects 0.000 claims 3
- 229960002179 ephedrine Drugs 0.000 claims 3
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 3
- 229960001022 fenoterol Drugs 0.000 claims 3
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 3
- 229940088597 hormone Drugs 0.000 claims 3
- 239000005556 hormone Substances 0.000 claims 3
- 229960001268 isoetarine Drugs 0.000 claims 3
- 229960001317 isoprenaline Drugs 0.000 claims 3
- 239000008101 lactose Substances 0.000 claims 3
- LMOINURANNBYCM-UHFFFAOYSA-N metaproterenol Chemical compound CC(C)NCC(O)C1=CC(O)=CC(O)=C1 LMOINURANNBYCM-UHFFFAOYSA-N 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- PLPRGLOFPNJOTN-UHFFFAOYSA-N narcotine Natural products COc1ccc2C(OC(=O)c2c1OC)C3Cc4c(CN3C)cc5OCOc5c4OC PLPRGLOFPNJOTN-UHFFFAOYSA-N 0.000 claims 3
- 229960004708 noscapine Drugs 0.000 claims 3
- 229960002657 orciprenaline Drugs 0.000 claims 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 229960002720 reproterol Drugs 0.000 claims 3
- WVLAAKXASPCBGT-UHFFFAOYSA-N reproterol Chemical compound C1=2C(=O)N(C)C(=O)N(C)C=2N=CN1CCCNCC(O)C1=CC(O)=CC(O)=C1 WVLAAKXASPCBGT-UHFFFAOYSA-N 0.000 claims 3
- IXTCZMJQGGONPY-XJAYAHQCSA-N rofleponide Chemical compound C1([C@@H](F)C2)=CC(=O)CC[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3O[C@@H](CCC)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O IXTCZMJQGGONPY-XJAYAHQCSA-N 0.000 claims 3
- 229950004432 rofleponide Drugs 0.000 claims 3
- 230000001225 therapeutic effect Effects 0.000 claims 3
- 229960000859 tulobuterol Drugs 0.000 claims 3
- 230000004584 weight gain Effects 0.000 claims 3
- 235000019786 weight gain Nutrition 0.000 claims 3
- 229940075420 xanthine Drugs 0.000 claims 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims 2
- 239000000443 aerosol Substances 0.000 claims 2
- 229960004217 benzyl alcohol Drugs 0.000 claims 2
- 229940112141 dry powder inhaler Drugs 0.000 claims 2
- 239000000843 powder Substances 0.000 claims 2
- 208000023504 respiratory system disease Diseases 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 206010057190 Respiratory tract infections Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229940071648 metered dose inhaler Drugs 0.000 claims 1
- ULSIYEODSMZIPX-UHFFFAOYSA-N phenylethanolamine Chemical compound NCC(O)C1=CC=CC=C1 ULSIYEODSMZIPX-UHFFFAOYSA-N 0.000 claims 1
- LERNTVKEWCAPOY-DZZGSBJMSA-N tiotropium Chemical compound O([C@H]1C[C@@H]2[N+]([C@H](C1)[C@@H]1[C@H]2O1)(C)C)C(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 LERNTVKEWCAPOY-DZZGSBJMSA-N 0.000 claims 1
- 229940110309 tiotropium Drugs 0.000 claims 1
- 208000011479 upper respiratory tract disease Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51507703P | 2003-10-28 | 2003-10-28 | |
| PCT/US2004/035129 WO2005044187A2 (en) | 2003-10-28 | 2004-10-22 | Inhalable pharmaceutical formulations employing lactose anhydrate and methods of administering the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007509941A JP2007509941A (ja) | 2007-04-19 |
| JP2007509941A5 true JP2007509941A5 (https=) | 2007-07-12 |
Family
ID=34572801
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006538128A Pending JP2007509941A (ja) | 2003-10-28 | 2004-10-22 | ラクトース無水物を用いる吸入医薬製剤およびその投与方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20070053843A1 (https=) |
| EP (1) | EP1686960A4 (https=) |
| JP (1) | JP2007509941A (https=) |
| CA (1) | CA2543482A1 (https=) |
| IL (1) | IL175032A0 (https=) |
| WO (1) | WO2005044187A2 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0501956D0 (en) * | 2005-01-31 | 2005-03-09 | Arrow Internat | Nebulizer formulation |
| GB0520794D0 (en) * | 2005-10-12 | 2005-11-23 | Innovata Biomed Ltd | Inhaler |
| CN101744792B (zh) * | 2008-12-17 | 2013-04-17 | 张凯 | 氟替卡松丙酸酯和沙美特罗昔萘酸酯复方干粉吸入剂及其制备工艺 |
| US9925282B2 (en) | 2009-01-29 | 2018-03-27 | The General Hospital Corporation | Cromolyn derivatives and related methods of imaging and treatment |
| US8834931B2 (en) | 2009-12-25 | 2014-09-16 | Mahmut Bilgic | Dry powder formulation containing tiotropium for inhalation |
| TR200909788A2 (tr) * | 2009-12-25 | 2011-07-21 | Bi̇lgi̇ç Mahmut | Tiotropyum içeren inhalasyona uygun kuru toz formülasyonu |
| EP2533765A2 (en) * | 2010-01-29 | 2012-12-19 | Mahmut Bilgic | Pharmaceutical compositions comprising formoterol and mometasone |
| TR201000685A2 (tr) * | 2010-01-29 | 2011-08-22 | Bi̇lgi̇ç Mahmut | Salmeterol ve flutikazon içeren farmasötik preparatlar. |
| US10105316B2 (en) | 2012-07-05 | 2018-10-23 | Arven llac Sanayi Ve Ticaret A.S. | Inhalation compositions comprising muscarinic receptor antagonist |
| WO2014007770A2 (en) * | 2012-07-05 | 2014-01-09 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Inhalation compositions comprising corticosteroid and sorbitol |
| US10111957B2 (en) | 2012-07-05 | 2018-10-30 | Arven Ilac Snayi ve Ticaret A.S. | Inhalation compositions comprising glucose anhydrous |
| AU2014261538A1 (en) * | 2013-04-29 | 2015-12-10 | Sanofi Sa | Inhalable pharmaceutical compositions and the inhaler devices containing them |
| TW201516023A (zh) | 2013-09-30 | 2015-05-01 | Daiichi Sankyo Co Ltd | 使用噴霧乾燥法之Ｄ－甘露醇α型結晶之選擇性製造方法 |
| CN110305095A (zh) * | 2013-10-22 | 2019-10-08 | 综合医院公司 | 色甘酸衍生物以及成像和治疗的相关方法 |
| WO2016037166A1 (en) * | 2014-09-07 | 2016-03-10 | Yu Zhang | Novel anti-oxidant compositions and methods of delivery |
| MX392636B (es) | 2014-10-31 | 2025-03-24 | Glaxosmithkline Ip Dev Ltd | Formulacion en polvo. |
| JP2019524865A (ja) | 2016-08-31 | 2019-09-05 | ザ ジェネラル ホスピタル コーポレイション | 神経変性疾患と関連する神経炎症におけるマクロファージ／ミクログリア |
| MX2021006869A (es) | 2018-12-10 | 2021-07-02 | Massachusetts Gen Hospital | Esteres de cromolin y usos de los mismos. |
| WO2021207060A1 (en) | 2020-04-06 | 2021-10-14 | The General Hospital Corporation | Methods of treatment of coronavirus-induced inflammation conditions |
| WO2022146914A1 (en) | 2020-12-28 | 2022-07-07 | The General Hospital Corporation | Cromolyn derivatives and uses thereof |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4778054A (en) * | 1982-10-08 | 1988-10-18 | Glaxo Group Limited | Pack for administering medicaments to patients |
| AU591152B2 (en) * | 1985-07-30 | 1989-11-30 | Glaxo Group Limited | Devices for administering medicaments to patients |
| US6536427B2 (en) * | 1990-03-02 | 2003-03-25 | Glaxo Group Limited | Inhalation device |
| GB9004781D0 (en) * | 1990-03-02 | 1990-04-25 | Glaxo Group Ltd | Device |
| SK280968B6 (sk) * | 1990-03-02 | 2000-10-09 | Glaxo Group Limited | Balenie medikamentu na použite v inhalačnom prístroji |
| PE44995A1 (es) * | 1994-01-27 | 1995-12-18 | Schering Corp | Furoato de mometasona para el tratamiento de las enfermedades pulmonares y de las vias respiratorias |
| GB9404945D0 (en) * | 1994-03-15 | 1994-04-27 | Glaxo Group Ltd | Pharmaceutical composition |
| HU219899B (hu) * | 1995-04-14 | 2001-09-28 | Glaxo Wellcome Inc. | Inhalálóberendezés flutikaszon-propionát adagolására mért dózisban |
| TR199701169T1 (xx) * | 1995-04-14 | 1998-03-21 | Glaxo Wellcome Inc. | Salmeterol i�in �l��lm�� doz inhaleri. |
| US6258341B1 (en) * | 1995-04-14 | 2001-07-10 | Inhale Therapeutic Systems, Inc. | Stable glassy state powder formulations |
| TR199701170T1 (xx) * | 1995-04-14 | 1998-02-21 | Glaxo Wellcome Inc. | Beklometazon dipropionat i�in �l��lm�� doz inhaleri. |
| HU219900B (hu) * | 1995-04-14 | 2001-09-28 | Glaxo Wellcome Inc. | Mért dózist adagoló inhalálóberendezés |
| GB9606188D0 (en) * | 1996-03-23 | 1996-05-29 | Danbiosyst Uk | Pollysaccharide microspheres for the pulmonary delivery of drugs |
| GB9626960D0 (en) * | 1996-12-27 | 1997-02-12 | Glaxo Group Ltd | Valve for aerosol container |
| GB9700226D0 (en) * | 1997-01-08 | 1997-02-26 | Glaxo Group Ltd | Inhalation device |
| US6495167B2 (en) * | 1997-03-20 | 2002-12-17 | Schering Corporation | Preparation of powder agglomerates |
| WO1998041193A1 (en) * | 1997-03-20 | 1998-09-24 | Schering Corporation | Preparation of powder agglomerates |
| EP0876814A1 (en) * | 1997-05-07 | 1998-11-11 | "PHARLYSE", Société Anonyme | Dry powder inhaler excipient, process for its preparation and pharmaceutical compositions containing it |
| TW533865U (en) * | 1997-06-10 | 2003-05-21 | Glaxo Group Ltd | Dispenser for dispensing medicament and actuation indicating device |
| GB2329939A (en) * | 1997-06-26 | 1999-04-07 | Glaxo Group Ltd | Self-lubricating valve stem for aerosol containers |
| PL200941B1 (pl) * | 1998-11-13 | 2009-02-27 | Jagotec Ag | Suchy proszkowy preparat inhalacyjny |
| US6390291B1 (en) * | 1998-12-18 | 2002-05-21 | Smithkline Beecham Corporation | Method and package for storing a pressurized container containing a drug |
| DK1292303T3 (da) * | 2000-02-17 | 2004-09-06 | Teva Pharma | Stabil farmaceutisk formulering omfattende torsemidmodifikation II |
-
2004
- 2004-10-22 JP JP2006538128A patent/JP2007509941A/ja active Pending
- 2004-10-22 CA CA002543482A patent/CA2543482A1/en not_active Abandoned
- 2004-10-22 WO PCT/US2004/035129 patent/WO2005044187A2/en not_active Ceased
- 2004-10-22 US US10/595,449 patent/US20070053843A1/en not_active Abandoned
- 2004-10-22 EP EP04796175A patent/EP1686960A4/en not_active Withdrawn
-
2006
- 2006-04-20 IL IL175032A patent/IL175032A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007509941A5 (https=) | ||
| US20230364015A1 (en) | Process for providing particles with reduced electrostatic charges | |
| Hou et al. | Practical, regulatory and clinical considerations for development of inhalation drug products | |
| HRP20200298T1 (hr) | Pripravci za respiratorno davanje aktivnih sredstava i pripadajući postupci i sustavi | |
| ES2983201T3 (es) | Composiciones, métodos y sistemas para la administración de fármacos en aerosol | |
| US20150150787A1 (en) | Compositions, methods & systems for respiratory delivery of three or more active agents | |
| CN101389341A (zh) | 用于加压计量吸入器的药物溶液制剂 | |
| JP2018199684A5 (https=) | ||
| JP2005539046A (ja) | 特異的な抗コリン作用薬、β−２アゴニスト、および副腎皮質ステロイドを含む、治療薬および組成物 | |
| JP2007507270A5 (https=) | ||
| JP2015519394A (ja) | キシナホ酸サルメテロール、プロピオン酸フルチカゾンおよび臭化チオトロピウムを含む吸入製剤用ドライパウダー、ならびにその製造方法 | |
| US20070053843A1 (en) | Inhalable pharmaceutical formulations employing lactose anhydrate and methods of administering the same | |
| JP2010500356A (ja) | ラクトースの製造方法 | |
| JP6653324B2 (ja) | 乾燥粉末製剤 | |
| WO2011045429A1 (en) | Improved formulations | |
| US20090298742A1 (en) | Process for manufacturing lactose | |
| JP2004529108A (ja) | Ｒ−サルメテロールおよびプロピオン酸フルチカゾンを含んでなる医薬製剤 | |
| CN105338967A (zh) | 包含布地奈德和福莫特罗的药物组合物 | |
| JP2006511297A (ja) | ベント型マウスピースを有する投薬システム | |
| Richardson et al. | Determination of the relative bioavailability of salbutamol to the lungs following inhalation from dry powder inhaler formulations containing drug substance manufactured by supercritical fluids and micronization | |
| JP5154732B2 (ja) | 薬剤 | |
| Scichilone et al. | Revising old principles of inhaled treatment in new fixed combinations for asthma | |
| Mack et al. | Drug delivery from a novel LAMA/LABA co-suspension technology of glycopyrrolate/formoterol fixed-dose combination MDI: evidence of consistency, robustness and patient-use reliability | |
| Molimard et al. | Inhalation devices for long-acting β2-agonists: efficiency and ease of use of dry powder formoterol inhalers for use by patients with asthma and COPD | |
| JP6653323B2 (ja) | 吸入可能な製剤 |